Factors Associated with Lung Function Decline in Patients with Non-Tuberculous Mycobacterial Pulmonary Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lee, Meng Rui ^a,b   Yang, Ching Yao ^a   Chang, Kai Ping ^a   Keng, Li Ta ^a,c   Yen, David Hung Tsang ^c,d   Wang, Jann Yuan ^a   Wu, Huey Dong ^a   Lee, Li Na ^a   Yu, Chong Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAO YUAN GENERAL HOSPITAL   (Taiwan)

^c Kinmen Hospital   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLARITHROMYCIN; CORTICOSTEROID; ETHAMBUTOL; IMIPENEM; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLINE; RIFAMPICIN;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM KANSASII; NON TUBERCULOUS MYCOBACTERIA PULMONARY DISEASE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

AGE FACTORS; AGED; BRONCHIECTASIS; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; LINEAR MODELS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84874624476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058214     Document Type: Article

References (30)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
2. Lee MR, Keng LT, Shu CC, Lee SW, Lee CH, et al. (2012) Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration. J Infect 64: 228-230.
3. Roberts MH, Mapel DW, (2012) Limited lung function: impact of reduced peak expiratory flow on health status, health-care utilization, and expected survival in older adults. Am J Epidemiol 176: 127-134.
4. Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, et al. (2009) Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J 33: 1025-1030.
5. Chung KP, Chen JY, Lee CH, Wu HD, Wang JY, et al. (2011) Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo) 66: 549-556.
6. Huang CT, Tsai YJ, Wu HD, Wang JY, Yu CJ, et al. (2012) Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 16: 539-545.
7. Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, et al. (2008) Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerging Infectious Diseases 14: 378-384.
8. Mehta M, Marras TK, (2011) Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 105: 1718-1725.
9. Khan Z, Miller A, Bachan M, Donath J, (2010) Mycobacterium Avium Complex (MAC) Lung Disease in Two Inner City Community Hospitals: Recognition, Prevalence, Co-Infection with Mycobacterium Tuberculosis (MTB) and Pulmonary Function (PF) Improvements After Treatment. Open Respir Med J 4: 76-81.
10. Shu CC, Lee CH, Hsu CL, Wang JT, Wang JY, et al. (2011) Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns. Lung 189: 467-474.
11. Wang JY, Lee LN, Chou CS, Huang CY, Wang SK, et al. (2004) Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 42: 4599-4603.
12. Wang JY, Hsueh PR, Wang SK, Jan IS, Lee LN, et al. (2007) Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore) 86: 39-46.
13. Brown-Elliott BA, Wallace RJ Jr, (2002) Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15: 716-746.
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, et al. (2005) General considerations for lung function testing. Eur Respir J 26: 153-161.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319-338.
16. Shu CC, Wu HD, Yu MC, Wang JT, Lee CH, et al. (2010) Use of High-Dose Inhaled Corticosteroids is Associated With Pulmonary Tuberculosis in Patients With Chronic Obstructive Pulmonary Disease. Medicine 89: 53-61.
17. Snider GL, Doctor L, Demas TA, Shaw AR, (1971) Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 103: 625-640.
18. Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, et al. (1992) Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 146: 855-859.
19. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554.
20. Wallace RJ, Zhang YS, Brown BA, Dawson D, Murphy DT, et al. (1998) Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 158: 1235-1244.
21. Griffith DE, Aksamit TR (2012) Bronchiectasis and Nontuberculous Mycobacterial Disease. Clin Chest Med 33: 283-+.
22. Sheehan RE, Wells AU, Copley SJ, Desai SR, Howling SJ, et al. (2002) A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 20: 581-587.
23. Lange P, Groth S, Nyboe GJ, Mortensen J, Appleyard M, et al. (1989) Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 2: 811-816.
24. Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, et al. (1990) Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 132: 685-700.
25. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ, (1986) Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 133: 974-980.
26. Burrows B, Knudson RJ, Camilli AE, Lyle SK, Lebowitz MD, (1987) The "horse-racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 135: 788-793.
27. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, et al. (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332-338.
28. Matveychuk A, Fuks L, Priess R, Hahim I, Shitrit D, (2012) Clinical and radiological features of Mycobacterium kansasii and other NTM infections. Respir Med 106: 1472-1477.
29. Lee MR, Cheng A, Huang YT, Liu CY, Chung KP, et al. (2012) Performance Assessment of the DR. TBDR/NTM IVD Kit for Direct Detection of Mycobacterium tuberculosis Isolates, Including Rifampin-Resistant Isolates, and Nontuberculous Mycobacteria. J Clin Microbiol 50: 3398-3401.
30. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, et al. (2011) Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183: 405-410.